Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 14, 2016 10:16 AM ET

Biotechnology

Company Overview of Enumeral Biomedical Holdings, Inc.

Company Overview

Enumeral Biomedical Holdings, Inc. engages in discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. It is developing antibodies against a number of classes of immunomodulatory proteins expressed on the surface of cells of the immune system for the treatment of cancer, autoimmune, and inflammatory diseases. Enumeral Biomedical Holdings, Inc. has a collaboration agreement with Merck Sharp & Dohme Corp. and The University of Texas MD Anderson Cancer Center; and research contract with the National Cancer Institute. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.

200 CambridgePark Drive

Suite 2000

Cambridge, MA 02140

United States

Founded in 2009

Phone:

617-945-9146

Key Executives for Enumeral Biomedical Holdings, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 48
Total Annual Compensation: $174.6K
Co-Founder and Executive Chairman
Age: 62
Total Annual Compensation: $167.4K
Chief Accounting Officer, Vice President of Finance and Treasurer
Age: 50
Total Annual Compensation: $85.4K
Compensation as of Fiscal Year 2014.

Enumeral Biomedical Holdings, Inc. Key Developments

Enumeral Biomedical Holdings, Inc. Enters Collaborative Research and Development Agreement with the University of Texas MD Anderson Cancer Center

Enumeral Biomedical Holdings, Inc. announced that it has entered into a Collaborative Research and Development Agreement with The University of Texas MD Anderson Cancer Center. Scientists from Enumeral and MD Anderson will collaborate on the discovery and development of novel monoclonal antibodies against specified targets in immuno-oncology, leveraging Enumeral’s antibody discovery and patient-centric immune profiling platform and MD Anderson’s preclinical and development expertise and infrastructure. Under the terms of the agreement, Enumeral and MD Anderson will share the costs of such research and development activities, and will each be granted the right to receive a percentage of the net income from product sales or any payments associated with licensing or otherwise partnering a program with a third party. ORBIT is a translational research platform of MD Anderson’s Moon Shots Program, which aims to accelerate the conversion of scientific knowledge into clinical advances that reduce cancer deaths.

Enumeral Biomedical Holdings, Inc. Presents at NobleCon12, the 12th Annual Emerging Growth Investor Conference, Jan-20-2016 10:00 AM

Enumeral Biomedical Holdings, Inc. Presents at NobleCon12, the 12th Annual Emerging Growth Investor Conference, Jan-20-2016 10:00 AM. Venue: Club Med Sandpiper Bay, Port St. Lucie, Florida, United States. Speakers: Arthur Tinkelenberg, Co-Founder, Chief Executive Officer, President and Director.

Enumeral Biomedical Holdings, Inc. Presents at Boston Biotech East West CEO Conference, Jan-10-2016 01:30 PM

Enumeral Biomedical Holdings, Inc. Presents at Boston Biotech East West CEO Conference, Jan-10-2016 01:30 PM. Venue: Four Seasons Hotel, 757 Market St., San Francisco, CA 94103, United States. Speakers: Arthur Tinkelenberg, Co-Founder, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Stability, Inc. United States
Cytopeia, Inc. United States
Promedior, Inc. United States
CMC ICOS Biologics Inc. United States
GenPhar, Incorporated United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Enumeral Biomedical Holdings, Inc., please visit www.enumeral.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.